Trilostane W311616 SHP099 exhibits dose-dependent pathway inhibition

SHP099 exhibits dose-dependent pathway inhibition and antitumor activity in xenograft models

AMPK α2β1γ1

CAS Number: 1262036-49-6

Chemical Name: 6-[3-(pyrrolidin-1-yl)propoxy]-2-{4-[3-(pyrrolidin-1-yl)propoxy]phenyl}-1

identified by a high-throughput

Trilostane W311616 SHP099 exhibits dose-dependent pathway inhibitionTrilostane is an inhibitor of 3 hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994. However, it was recently approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs. It is also the first drug approved to treat both pituitary and adrenal dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in